Opportunities for Healthy Volunteers

Contribute to medical research by participating in studies designed for healthy participants in your selected area.

Matched clinical trials

  • A study of PF-08634404 and a drug combination in adults with advanced or metastatic non-small cell lung cancer

    Recruiting

    3 1 1
    Czechia France Germany Greece Hungary Italy +2
  • A study to evaluate the effectiveness of levosimendan in patients with pulmonary hypertension and heart failure with preserved ejection fraction.

    Recruiting

    3 1
    Investigated Diseases:
    Investigated Drugs:
    Austria Bulgaria Czechia France Germany Hungary +3
  • A Study Comparing PF-08634404 and a Drug Combination with Chemotherapy in Adults with Metastatic Colorectal Cancer

    Recruiting

    3 1 1 1
    Belgium Denmark France Germany Italy The Netherlands +2
  • A study to compare the effects of BI 690517 and spironolactone on kidney function in patients with heart failure, cardiovascular disease, or chronic kidney disease

    Recruiting

    2 1 1 1
    The Netherlands
  • Study of fludarabine phosphate in patients with blood cancer undergoing lymphodepletion before CAR-T cell therapy

    Recruiting

    3 1 1 1
    Investigated Diseases:
    Belgium
  • A study of ACR-368 and gemcitabine for patients with endometrial cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    France Germany Italy Spain
  • Study of zenagamtide for weight loss and sleep improvement in patients with obesity and obstructive sleep apnea using positive airway pressure therapy

    Recruiting

    3 1
    Investigated Diseases:
    Germany Poland Spain
  • A study of mRNA-4157 and a drug combination for patients with stage IV non-small cell lung cancer

    Recruiting

    2 1 1
    France Italy Poland Spain
  • A study to evaluate the effectiveness and safety of NBI-1117570 in adults with schizophrenia who require hospital treatment.

    Recruiting

    2 1
    Investigated Drugs:
    Bulgaria Croatia Poland Romania
  • Study of inavolisib, ribociclib, and fulvestrant for patients with advanced hormone-receptor-positive, HER2-negative breast cancer.

    Recruiting

    2 1 1
    France Germany Italy Poland Spain